

1 **Title:** Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase and  
2 ethanalamides metabolism with Alzheimer's disease

3

4 **Author:** Kamil Borkowski<sup>1</sup>, Theresa L. Pedersen<sup>2</sup>, Nicholas T. Seyfried<sup>3</sup>, James J. Lah<sup>4</sup>, Allan I.  
5 Levey<sup>4</sup>, Chadwick M. Hales<sup>4</sup>, Eric B. Dammer<sup>3</sup>, Colette Blach<sup>5</sup>, Gregory Louie<sup>6</sup> Rima  
6 Kaddurah-Daouk<sup>7</sup>, John W. Newman<sup>1,8,9</sup> and Alzheimer's Disease Metabolomics Consortium

7

8

9 **Author affiliations:**

10 1 – West Coast Metabolomics Center, Genome Center, University of California Davis, Davis,  
11 CA 95616, USA.

12 2 – Dept Food Science and Technology, University of California - Davis, Davis, CA 95616,  
13 USA.

14 3 – Department of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322,  
15 USA

16 4 – Department of Neurology, Emory University, Atlanta, GA, 30329 USA

17 5 – Duke Molecular Physiology Institute, Duke University, Durham, NC, 27708 USA

18 6 – Department of Psychiatry and Behavioral Sciences, Duke University, Durham NC 27708,  
19 USA.

20 7 – Department of Psychiatry and Behavioral Sciences, Duke Institute for Brain Sciences and  
21 Department of Medicine, Duke University, Durham NC 27708, USA.

22 8 – Western Human Nutrition Research Center, United States Department of Agriculture -  
23 Agriculture Research Service, Davis, CA 95616, USA.

24 9 – Department of Nutrition, University of California - Davis, Davis, CA 95616, USA.

25

26 \* Corresponding author: [kborkowski@ucdavis.edu](mailto:kborkowski@ucdavis.edu)

27

28

29

30

31

32

33

34

35

36

37

38

39 Abstract

40 Alzheimer's disease shares inflammatory origin with cardiometabolic disorders. Lipid mediators,  
41 including oxylipins, endocannabinoids, bile acids and steroids are potent regulators of  
42 inflammation, energy metabolism and cell proliferation with well-established involvement in  
43 cardiometabolic diseases. However, their role in Alzheimer's disease is poorly understood. In the  
44 current study we provide comprehensive analysis of plasma and CSF lipid mediators in a case-  
45 control comparison of patients with Alzheimer's disease, utilizing a targeted quantitative mass  
46 spectrometry approach. In both plasma and CSF, we observed Alzheimer's disease patients to  
47 have elevated components of cytochrome P450/soluble epoxide hydrolase pathway and lower  
48 levels of fatty acids ethanolamides, when compared to the healthy controls. Multivariate analysis  
49 revealed that circulating metabolites of soluble epoxide hydrolase together with ethanolamides  
50 are strong and independent predictors for Alzheimer's disease. Both metabolic pathways are  
51 potent regulators of inflammation with soluble epoxide hydrolase being reported to be  
52 upregulated in the brains of Alzheimer's disease patients. This study provides further evidence  
53 for the involvement of inflammation in Alzheimer's disease and argues for further research into  
54 the role of the cytochrome P450/soluble epoxide hydrolase pathway and fatty acid ethanolamides  
55 in this disorder. Further, these findings suggest that a combined pharmacological intervention  
56 targeting both metabolic pathways may have therapeutic benefits for Alzheimer's disease.

57

58

59

60

## 61 **Introduction**

62 Risk factors for Alzheimer's disease (AD) include cardiometabolic disorders, low-grade  
63 systemic inflammation and altered lipid and energy metabolism [1-3]. Lipid mediators are lipid  
64 derived signaling molecules that regulate both acute and low-grade systemic inflammation and  
65 energy metabolism along with other processes [4]. Circulating lipid mediators have been  
66 implicated in the pathogenesis of cardiometabolic diseases [5-7], however, their involvement in  
67 AD is still not well described.

68 Four important families of such lipid mediators readily detected in the circulation are the  
69 oxygenated polyunsaturated fatty acids (i.e. oxylipins), the endogenous cannabinoid receptor  
70 activators and their structural equivalents (i.e. endocannabinoids, including monoacylglycerols  
71 and ethanolamides), bile acids and steroids. Oxylipins are mainly oxygenated products of  
72 polyunsaturated fatty acids (PUFAs) generated *via* 4 main pathways: cyclooxygenases (COX),  
73 generating mainly prostaglandins; lipoxygenases (LOX), generating mainly hydroxy-fatty acids,  
74 including leukotrienes and lipoxins; cytochrome P450 (CYP) and soluble epoxide hydrolase  
75 (sEH), generating epoxy-fatty acids and dihydroxy fatty acids respectively [4], and reactive  
76 oxygen-mediated formation of prostanoids and hydroxy-fatty acids (REF). Products from these  
77 pathways exhibit both pro- and anti-inflammatory actions (REF). Endocannabinoids are mainly  
78 fatty acids esters and amides, which are ligands for the cannabinoid receptors CB1 and CB2, the  
79 transient potential vanilloid receptor TRPV1 and G- protein-coupled receptor GPR55 [8], all  
80 highly expressed in the central nervous system [9]. Endocannabinoids regulate energy  
81 metabolism [8] and are generally consider anti-inflammatory [10]. Bile acids (BA) are generated  
82 by the liver as primary bile acids and secreted into the gut to aid in lipid digestion, and they are  
83 further metabolized by the gut microbiome form secondary bile acids [11]. After reabsorption

84 from the gut into the blood stream, BAs regulate energy metabolism with different potency  
85 between primary and secondary species [12].

86 Changes in circulating lipid mediators in relation to AD were previously reported.  
87 Particularly, several oxylipins of the acute inflammation pathway were reportedly elevated in  
88 AD [13, 14] and pro-resolving (quenching activated inflammatory signal) lipid mediators have  
89 been suggested as potential treatment for AD [15]. Specific changes in bile acids metabolism,  
90 including a decrease in primary and an increase in secondary metabolites were also observed in  
91 AD subjects [16] and differences in bile acids clearance for cholesterol pathway were reported in  
92 AD [17]. Notably, bile acids and some steroids manifest neuroprotective functions through  
93 activation of steroid receptors [18]. However, a comprehensive analysis of the AD related  
94 changes in circulating lipid mediators is lacking and reports of lipid mediators in cerebrospinal  
95 fluid (CSF) are minimal. In the current work we utilize plasma and CSF samples of AD patients  
96 and cognitively normal controls from the Emory Goizueta Alzheimer's Disease Research Center  
97 (ADRC). Using a case control approach, we provide comprehensive analysis of AD-associated  
98 changes in both circulating and CSF lipid mediators, including major classes of oxylipins,  
99 endocannabinoids, bile acids and some steroids, covering multiple aspects of inflammatory  
100 cascades and regulators of energy metabolism. Moreover, to minimize the bias caused by  
101 postprandial fluctuation in plasma lipids, the fasting state of opportunistically collected samples  
102 was estimated using a novel predictive model that uses levels of circulating lipid mediators [19].

103

104 **Materials and methods**

105 **Subjects:** All participants from whom plasma and CSF samples were collected provided  
106 informed consent under protocols approved by the Institutional Review Board at Emory  
107 University. Cohorts included the Emory Healthy Brain Study (IRB00080300), Cognitive  
108 Neurology Research (IRB00078273), and Memory @ Emory (IRB00079069). All protocols  
109 were reviewed and approved by the Emory University Institutional Review Board. All patients  
110 received standardized cognitive assessments (including Montreal Cognitive Assessment  
111 (MoCA)) in the Emory Cognitive Neurology clinic, the Emory Goizueta Alzheimer's Disease  
112 Research Center (ADRC) and affiliated Emory Healthy Brain Study (EHBS) [20]. All diagnostic  
113 data were supplied by the ADRC and the Emory Cognitive Neurology Program. CSF was  
114 collected by lumbar puncture and banked according to 2014 ADC/NIA best practices guidelines.  
115 All CSF samples collected from research participants in the ADRC, Emory Healthy Brain Study,  
116 and Cognitive Neurology clinic were assayed using the INNO-BIA AlzBio3 Luminex assay at  
117 AKESOgen (Peachtree Corners, GA). AD cases and healthy individuals were defined using  
118 established biomarker cutoff criteria for AD for each assay platform [21, 22]. In total, plasma  
119 samples were available for 148 AD patients and 133 healthy controls and CSF samples were  
120 available for 150 AD patients and 139 healthy controls. Plasma and CSF sample collection  
121 overlap (both plasma and CSF collected at the same day) was 145 for AD group and 133 for the  
122 control group. Cohort information is provided in **Table S1**.

123

124 **Quantification of lipid mediators:** Plasma concentrations of non-esterified PUFA, oxylipins,  
125 endocannabinoids, a group of non-steroidal anti-inflammatory drugs (NSAIDs) including  
126 ibuprofen, naproxen, acetaminophen, a suite of conjugated and unconjugated bile acids, and a

127 series of glucocorticoids, progestins and testosterone were quantified in 50 $\mu$ L of plasma by  
128 liquid chromatography tandem mass spectrometry (LC-MS/MS) after protein precipitation in the  
129 presence of deuterated metabolite analogs (i.e. analytical surrogates) [23]. CSF analyses were  
130 performed with 100 $\mu$ L samples prepared as previously reported for the analyses of sweat [24]  
131 and analyzed as reported for plasma. All samples were processed with rigorous quality control  
132 measures including case/control randomization, and the analysis of batch blanks, pooled matrix  
133 replicates and NIST Standard Reference Material 1950 – Metabolites in Human Plasma (Sigma-  
134 Aldrich, St Louis, MO). Extraction batches were re-randomized for acquisition, with method  
135 blanks and reference materials and calibration solutions scattered regularly throughout the set.  
136 Instrument limits of detection (LODs) and limits of quantification (LOQs) were estimated  
137 according to the Environmental Protection Agency method (40 CFR, Appendix B to Part 136  
138 revision 1.11, U.S. and EPA 821-R-16-006 Revision 2). These values were then transformed into  
139 sample nM concentrations by multiplying the calculated concentration by the final sample  
140 volume and dividing by the volume of sample extracted. A complete analyte list with plasma  
141 LODs and LOQs have been reported [23]. The majority of analytes were quantified against  
142 analytical standards with the exception of eicosapentaenoyl ethanolamide (EPEA), palmitoleoyl  
143 ethanolamide (POEA), and the measured PUFAs [i.e. linoleic acid (LA); alpha-linolenic acid  
144 (aLA); arachidonic acid (AA); eicosapentaenoic acid (EPA); docosahexaenoic acid (DHA)]. For  
145 these compounds, area counts were recorded, adjusted for deuterated-surrogate responses and the  
146 relative response factors were expressed as the relative abundance across all analyzed samples.  
147 Reported monoacylglycerols (MAGs) are the sum of 1- and 2-acyl isomers, due to isomerization  
148 during sample processing.

149

150 ***Fasting state assessment and sample selection:*** Many of the CSF and plasma samples from AD  
151 patients were collected following additional research consent in the course of patients' clinical  
152 evaluations. Lumbar puncture procedures were nearly all scheduled in the morning, but fasting  
153 was not mandated in these individuals. Therefore, fasting state of the samples was estimated  
154 using previously published predictive equation, based on the raw plasma levels of 12(13)-  
155 EpOME, GCDCA and NO-Gly [19]. Only subjects with the probability of the fasting state >  
156 60% were used for the plasma analysis. All subjects were used to compare lipid mediators level  
157 in CSF. CSF was reported not to manifest postprandial lipid fluctuations [25], additionally,  
158 comparing predicted fasted to predicted non-fasted AD subjects reveal minimal differences in  
159 only 2 metabolites (**Table S2**).

160

161 ***Statistical analysis:*** All statistical tests were performed using JMP Pro 14 (JMP, SAS institute,  
162 Carry, NC). Prior to analysis, data were tested for outliers using the robust Huber M test and  
163 missing data were imputed using multivariate normal imputation for variables which were at  
164 least 75% complete. The imputed numbers constitute less than 3% of the data for both plasma  
165 and CSF. Imputation facilitated multivariate data analysis and non-imputed data were used for  
166 univariate approaches. Additionally, variables were normalized, centered, and scaled using  
167 Johnson's transformation, with normality verification using the Shapiro-Wilk test. The difference  
168 between the control and the AD group were assessed using t-test with gender, age, and race as  
169 covariates. Additionally, two-way ANOVA was used to test for the gender x group and race x  
170 group interactions. In case of significant interaction, the group effect was tested separately for  
171 the interacting factor. Correlations between MoCA score and lipid mediators were assessed using  
172 Spearman's rank order correlation, to account for non-linear associations. This analysis was



173 performed using only AD subjects, stratified by the assessed fasting state for plasma. CSF  
174 samples were analyzed without fasting state stratification. Multiple comparison control was  
175 accomplished with the false discovery rate (FDR) correction method of Benjamini and Hochberg  
176 with a  $q = 0.2$  [26].

177 Predictive models for AD were prepared using a combination of bootstrap tree and  
178 stepwise logistic regression modeling. Prior to analysis, subjects were randomly split into  
179 training (70%) and validation (30%) cohorts. Variables most frequently appearing in the models  
180 were identified by bootstrap tree: Number of layers = 50; split per tree = 3, bootstrap sampling  
181 rate for variables and subjects = 1. A variable contribution scree plot was generated using  
182 variable rank and the likelihood ratio of chi-square. The scree plot was used to determine a  
183 likelihood ratio of chi-square cutoff value for variables contributing to the model. Selected  
184 variables were then subjected to stepwise logistic regressions. A stepwise analysis was  
185 performed with the maximal validation  $r^2$  as the model stopping criteria, or if an additional step  
186 increased the Bayesian information criteria (BIC). Variables selected by the stepwise approach  
187 were then used to build the model using logistic regression. Metabolites that the model  
188 contribution  $p$ -value  $< 0.05$  were excluded, to ensure the strongest model with the minimal  
189 number of predictors.

190 Partial least square discriminant analysis (PLA-DA) was used to integrate AD related  
191 differences in metabolite levels between plasma and CSF. PLS-DA model was built using the  
192 nonlinear iterative partial least squares algorithm with K-Fold variation method ( $k = 7$ ) and  
193 included 235 variables from plasma and CSF, including metabolite levels and informative  
194 metabolite ratios. For the clarity purpose, only variables with a variable importance in projection  
195 (VIP) score  $> 1.4$  we displayed on the loading plot.

196 Correlation between CSF and plasma metabolites was assessed using Spearman's rank  
197 order correlation.

198

## 199 **Results**

200 ***Fasting state assessment:*** Analysis of opportunistically collected samples brings a challenge of  
201 the unknown fasting state. The control cohort contained samples collected in the fasted state per  
202 ADRC and EHBS protocols, but the AD cohort included many who had no collected fasting state  
203 information and consist of samples collected in both fasted and non-fasted states. Therefore, to  
204 allow a direct comparison of the control and AD groups, we assessed the estimated subject  
205 fasting state using our previously published predictive model [19]. As expected, control group  
206 was predicted to contain mostly fasted subjects (**Figure S1**). Out of 133 control subjects, 105  
207 (i.e. 79%) were predicted as fasted, while 17 (i.e. 12%) as non-fasted, with a probability of >60%  
208 and 11 (i.e. 8%) had a fasting state probability of <60%. Out of 148 AD subjects, 60 (i.e. 40%)  
209 were predicted as fasted and 81 (i.e. 55%) as non-fasted, with a probability of >60% and 7 (5%)  
210 had a fasting state probability of <60%. Fifty percent of detected metabolites manifested  
211 difference between predicted fasted and non-fasted AD subjects in plasma and only minimal  
212 differences were observed in CSF (**Table S2**).

213

214 ***Cytochrome P450/soluble epoxide hydrolase metabolism is elevated in AD subjects:*** We  
215 compared plasma and CSF lipid mediator concentrations between the control and the AD groups,  
216 using only estimated fasted subjects with probability>60% for plasma. In plasma, we detected 42  
217 oxylipins (85 measured), 5 PUFAs (5 measured), 17 endocannabinoids (22 measured), 3

218 NSAIDs (4 measured), 19 bile acids (23 measured) and 8 steroid hormones (8 measured). The  
219 mean values and p-values for t-tests and two-way ANOVA interactions for all detected  
220 metabolites are provided in **Table S3**. Plasma group-fold differences in the oxylipin,  
221 endocannabinoids and PUFAs, projected onto their metabolic pathway, are presented in **Figure**  
222 **1**. The largest differences were observed in the long chain omega-3 PUFA metabolism. Both  
223 EPA and DHA enzyme derived mono-alcohols (5-LOX-derived 5-HEPE and 4-HDoHE and 12-  
224 LOX-derived 12-HEPE and 14-HDoHE) were lower (1.5-fold in average) in the AD group,  
225 when compared to the control. On the other hand, the sEH EPA metabolite 17,18-DiHETE, was  
226 3-fold higher in the AD group. In the AD group, the AA pathway manifested lower levels of the  
227 COX derived prostaglandins PGF2 $\alpha$  and PGD2 (1.6-fold average). Additionally, the AD group  
228 showed lower levels of acylethanolamides (1.5-fold in average) derived from dihomo-gamma-  
229 linolenic acid (DGLA), AA (AEA), docosatetraenoic acid (DEA), DHA (DHEA) and oleic acid  
230 (OEA). Notable are also lower levels of autooxidation markers, particularly the EPA-derived 9-  
231 HEPE (2-fold), linoleic acid (LA) -derived TriHOMEs (1.65-fold) and AA-derived isoprostanes  
232 (1.3-fold) in AD group.

233 Fewer lipid mediators were detected in CSF than in plasma. Detected CSF lipid  
234 mediators included 17 oxylipins, 5 PUFAs, 3 endocannabinoids, 14 bile acids and 6 steroids. The  
235 mean values and p-values for t-tests and two-way ANOVA interactions are provided in **Table**  
236 **S4**. CSF significant group-fold differences in the level of oxylipin, endocannabinoids and  
237 PUFAs, projected onto their metabolic pathway, are presented in **Figure 2**. In this matrix, the  
238 largest differences were observed in the LA CYP metabolic pathway, where both epoxy and  
239 dihydroxy FA, products of CYP and subsequent sEH metabolism, were higher in the AD group  
240 when compared to the control: epoxide average 1.5-fold; diol average 1.3-fold. All PUFAs from

241 both omega-3 and omega-6 pathway were lower in the AD group, although the difference was  
242 only 1.2-fold on average. Additionally, AD group manifested 1.5-folds lower level of OEA and  
243 1.3-fold lower level of the EPA-derived 14,15-DiHETE.

244 While few differences were observed in plasma and CSF bile acid levels between control  
245 and AD subjects, numerous differences were present in the specific bile acid ratios (**Table 1**).  
246 **Figure S2** shows bile acids metabolic pathway together with their median plasma levels to help  
247 understand the biological aspects of specific bile acid ratios. In plasma, the AD group was  
248 characterized by lower levels of cholic acid (CA), a product of the neutral bile acids synthesis  
249 pathway, while chenodeoxycholic acid (CDCA), a product of the acidic pathway was unchanged.  
250 This difference becomes even more pronounced when looking at the CA/CDCA ratio. On the  
251 other hand, the difference between neutral and acidic pathway was not present in downstream  
252 metabolites, when comparing the secondary unconjugated bile acids ratio, like deoxycholic  
253 acid/(lithocholic acid + ursodeoxycholic acid) (DCA/(LCA+UDCA)) or the most abundant  
254 primary conjugated derivatives glycocholic acid/glycochenodeoxycholic acid (GCA/GCDCA);  
255 **Table S3**. Of note, small differences between the neutral and acidic pathway were observed in  
256 the low abundance taurine conjugates of the secondary bile acids  
257 taurodeoxycholic/taurolithocholic acid (TDCA/TLCA). Difference in conjugation ratio (more  
258 conjugates than the substrate) was observed in the neutral synthesis pathway (GDCA/DCA and  
259 GCA/CA) but not in the acidic synthesis pathway. Differences between the neutral and acidic  
260 synthesis pathway were also observed in the conversion of the primary to secondary bile acids.  
261 The ratio of downstream products to their precursor in the neutral pathway was higher in the AD  
262 group in the case of DCA/CA, TDCA/CA and GDCA/CA, but not in parallel acidic pathway  
263 metabolites (i.e. LCA/CDCA, UDCA/CDCA).

264 CSF manifested few differences in bile acids and their ratios. The AD group had 1.3-fold  
265 higher levels of GLCA and 1.4-fold higher level of T-a-MCA. Additionally, AD group had lower  
266 ratio of GCDCA/GLCA (1.3-folds, **Table S4**).

267 Of those measured, only a few steroid hormones showed different levels between AD and  
268 the control. In plasma, dehydroepiandrosterone sulfate (DHEAS) and progesterone were lower in  
269 AD group (1.9 and 1.7-folds respectively). Additionally, testosterone and the  
270 testosterone/progesterone ratio showed significant gender x group interaction. Females AD  
271 subjects showed 1.4-fold lower testosterone, when compared to females controls, but no  
272 differences were observed in males. On the other hand, the testosterone/progesterone ratio was 2-  
273 fold higher in AD male subjects compared male controls. Testosterone/progesterone ratio  
274 differences were not observed in females.

275 In CSF, only corticosterone showed a significant difference between AD and the control group,  
276 however, the magnitude of the-fold difference only ~1.1.

277

#### 278 **Relation between CSF and plasma AD markers.**

279 In the current study, matched plasma and CSF samples were collected, allowing an assessment of  
280 the relationships between metabolites in these pools. Spearman's  $\rho$  rank order correlation  
281 between plasma and CSF lipid mediator levels are shown in **Table 2**. The associations were  
282 distinct by metabolite classes, with oxylipins showing only 2 of 15 significant correlations, while  
283 bile acids and steroids showing 14 of 18 significant correlations. Correlations within PUFA and  
284 PUFA ethanolamide were also apparent for the long chain omega 3 species (DHA EPA and  
285 DHA ethanolamide) but not others.

286 Next, we used partial least square discriminant analysis (PLS-DA) to illustrate the  
287 relationship between plasma and CSF AD markers (**Figure 3**). The analysis showed that  
288 discrimination between control and AD was dominated by the plasma metabolites. Fifteen  
289 plasma metabolites (and their ratios) manifested variable importance in projection (VIP) score  
290 >1.4 compared to only 4 CSF metabolites. The discrimination between AD and the control group  
291 was characterized by higher plasma 17,18-DiHETE (VIP = 2.16) and CSF EpOMES (VIP = 1.95  
292 and 1.58 for the 12(13) and 9(10) isoforms respectively) and lower levels of the  
293 acylethanolamide ratios including both DHEA/LEA and DEA/LEA in plasma and both plasma  
294 and CSF OEA/LEA. Plasma and CSF OEA/LEA manifest similar discriminatory power based on  
295 their proximity on the loading plot. On the other hand, plasma 17,18-DiHETE and CSF EpOMES  
296 occupied distinct parts of the loading plot, suggesting distinct discriminatory properties. The  
297 VIPs for each metabolite are provided in the **Table S5**.

298

299 ***Fatty acid ethanolamides and CYP/sEH metabolites are strong AD predictors in both plasma***  
300 ***and CSF.*** We used predictive modeling to investigate how well plasma and CSF metabolites can  
301 report AD status. Plasma lipid mediators generated stronger models than those in CSF with area  
302 under the receiver operator characteristic curves (ROC AUC) of 0.924 vs. 0.824, with the two  
303 models consisting of distinct metabolites (**Figure 4**). However, in both matrices, the strongest  
304 predictors belonged to the same two metabolic pathways, the acyl ethanolamides and CYP/sEH  
305 pathway. Plasma predictors included ethanolamides (OEA and DEA normalized to the LEA  
306 level), the 12,13-DiHOME/EpOME an indicator of sEH activity [27] and sEH metabolite of AA  
307 (14,15-DiHETrE). In CSF, the strongest predictors included OEA/LEA and the linoleate-derived  
308 epoxides 12(13)-EpOME and 9(10)-EpOME. When plasma and CSF markers were combined in

309 predictive model efforts, the resulting model consisted uniquely of ethanolamides, including  
310 plasma long chain PUFA ethanolamides (DEA/LEA and DHEA/LEA) and CSF OEA/LEA. This  
311 model resulted in the ROC AUC of 0.889.

312 For all 3 models, ethanolamides OEA, DEA and DHEA were stronger predictors when  
313 used as a ratio to LA derived ethanolamide – LEA. LEA itself was not different between AD and  
314 the control group in either plasma or CSF (**Figure 1** and **Figure 2**) unlike OEA, DEA and  
315 DHEA. Therefore, LEA likely serves as a surrogate for the general acyl-ethanolamides level and  
316 adjustment of other ethanolamides by LEA lowers intra-individual variability.

317

318 ***Lipid mediator–cognitive score associations in AD.*** The AD cohort is characterized by a high  
319 log(t-Tau/A $\beta$ 42) ratio and MoCA scores ranging from normal cognitive function to severe  
320 cognitive impairment (**Figure S3**). Taking advantage of the broad MoCA range, we investigated  
321 lipid mediator associations with cognitive function in this group pathological levels of t-  
322 Tau/A $\beta$ 42. Additionally, since the AD cohort was represented by subjects in both fasted and non-  
323 fasted states, we stratified the analysis by fasting state for plasma samples (**Table 3**). In the  
324 fasting state, PUFA oxidation markers, 5,15-DiHETE and 9-HETE were negatively associated  
325 with the MoCA score (although only 5,15-DiHETE passed FDR correction). 5,15-DiHETE can  
326 have enzymatic or autooxidative origin, whereas 9-HETE is a strictly an autooxidative product.  
327 5,15-DiHETE correlated with 9-HETE in fasted subjects with an  $R^2=0.415$  ( $n=60$ ;  $p < 0.001$ ). In  
328 non-fasted AD subjects, a strong positive association between the MoCA score and EPA-derived  
329 ethanolamide (EPEA) as well as the levels of EPA and DHA were observed. Additionally, a  
330 positive correlation was detected between MoCA and the EPA-derived 17,18-DiHETE, the

331 DHA-derived 14-HDoHE and the 18 carbon PUFAs (LA and ALA), however, these did not pass  
332 FDR correction.

333 In CSF, the linoleic acid derived epoxides 12(13)- and 9(10) -EpOMEs showed weak but  
334 significant positive correlations with MoCA ( $\rho > 0.2$ ,  $p < 0.005$ ; **Table 4**). Additionally, positive  
335 associations were observed between MoCA and DHA and DHA derived diol (19,20-DiHDoPE)  
336 and conjugated bile acids GCA (and the ratio of GCA to GDCA and GCDCA), TCDCA and the  
337 conjugated to unconjugated ratio for DCA and CDCA (GCA/GCDCA, GCDCA/CDCA and  
338 TCDCA/CDCA). However, only linoleic acid epoxides passed the FDR correction.

339

## 340 **Discussion**

341 Metabolic disruptions influencing vascular physiology, inflammation and energy metabolism  
342 have been reported to increase the risk of Alzheimer's disease, however whether these changes  
343 are independent risk factors or how they may interact has not been well established. If novel  
344 biomarkers of AD can be identified within these domains, they could not only provide useful  
345 screening and risk assessment tools but may also provide insight into connections between  
346 metabolism and neurodegenerative diseases. To this end, we performed a comprehensive  
347 analysis of plasma and CSF lipid mediators, endogenous regulators of multiple processes  
348 including inflammation and energy metabolism and described their associations with AD and  
349 cognitive function. In the process, we identify clear differences between AD and healthy  
350 controls in two metabolic pathways, CYP/sEH and fatty acids-derived ethanolamides, and subtle  
351 differences in bile acids and steroids.



352 AD-associated differences in plasma bile acid were in agreement with previously  
353 reported analyses of The Religious Orders Study and the Rush Memory and Aging Project  
354 (ROS/MAP) cohort [16]. These included lower levels of CA and the CA:CDCA ratio in AD,  
355 suggesting that the neutral bile acid synthesis pathway could be affected in AD. There are few  
356 studies regarding the shift between neutral and acidic BA synthesis, one of them reporting an  
357 increase in neutral/acidic pathway products ratio in nonalcoholic steatohepatitis [28]. However,  
358 the biological relevance of this difference in terms of AD is yet to be determined. Interestingly,  
359 we previously reported associations between postprandial bile acids and cognition, with few  
360 associations in the fasting state [19]. Considering that the current manuscript focuses on AD  
361 related differences in the fasting state, further studies probing postprandial bile acid metabolism  
362 and AD are suggested. Interestingly, several bile acid and steroid differences in AD were gender  
363 specific. Few studies reports gender specific action of TUDCA and UDCA on ER stress markers  
364 in rodent model for the prion disease [29]. These findings further support the importance of  
365 gender focused approaches when investigating cholesterol-derived metabolism in the context of  
366 AD, as established with regards to the links between ApoE4 and AD risk in post-menopausal  
367 women [30].

368 With respect to fatty acid metabolism, our study identified substantial AD-associated  
369 elevations in CYP/sEH pathway products and lower levels of acylethanolamides in both plasma  
370 and CSF, although different elements of these pathways were affected in plasma and CSF.  
371 Oxylipin and endocannabinoid levels show no association between plasma and CSF, suggesting  
372 independent regulation of these pools. Likewise, CYP/sEH metabolites of plasma and CSF  
373 manifest distinct discriminatory power in PLS-DA models of AD. On the other hand, CSF and  
374 plasma acylethanolamides seem to manifest similar AD discriminatory power and can be

375 substituted in the AD predictive model. These findings are consistent with previous reports  
376 implicating both CYP/sEH metabolites and acylethanolamides as important regulators of  
377 inflammation in neurodegenerative disorders [10, 31, 32].

378 In the CYP/sEH pathway, polyunsaturated fatty acids are converted to anti-inflammatory  
379 and vasodilating epoxy fatty acids by CYPs, which are further metabolized to pro-inflammatory  
380 and vasoconstricting diols by sEH, a process primarily recognized in cardiovascular disease [33].  
381 In the current study, we found higher plasma level of the EPA sEH metabolite 17,18-DiHETE in  
382 AD patients, but only slight difference in the parallel AA metabolites were observed. Notably,  
383 EPA metabolites derived from LOX pathways were lower in AD patients, suggesting that the  
384 observed differences are not a result of differential omega-3 fatty acid intake, but rather specific  
385 enhancement in sEH-dependent EPA metabolism. Omega-3 sEH metabolites are particularly  
386 potent regulators of the cardiovascular system, especially blood vessel tone and vascular  
387 inflammation [34] and sEH inhibitors have been suggested to improve outcomes for both  
388 cardiovascular [35] and neurodegenerative diseases [36]. Clinical associations between  
389 cardiovascular disease and AD have been reported, where the regulation of a vascular tone and  
390 blood flow play a role in both pathologies [37]. Additionally, we previously reported plasma  
391 EPA sEH metabolites to be negatively associated with perceptual speed in cognitively normal  
392 subjects [19]. Therefore, the current findings further support involvement of vascular  
393 dysfunction in AD, perhaps through alterations to the blood brain barrier and vascular-related  
394 inflammatory signaling, with overlapping molecular mechanisms leading to cardiovascular and  
395 neurodegenerative pathologies. When considering these shifts in oxylipin profiles, it is  
396 important to remember that an epoxides reservoir is generated by esterification into phospholipid  
397 membranes [38], whereas diols are not readily reincorporated into the membranes and rapidly

398 appear in the free pool and are actively excreted from cells [39]. Since tissue esterified lipid  
399 mediators were not evaluated in these samples, it is difficult to know whether the observe  
400 difference in EPA diol was due to an increased production of CYP/sEH metabolites or increased  
401 clearance of membrane bound EPA epoxides, and future studies are needed to resolve this issue.

402 In contrast to plasma, CSF showed higher levels of LA-derived epoxides, along with a  
403 moderate increase in LA-diols, but not CYP/EH metabolites of longer chain PUFAs. The source  
404 of the CSF metabolites is likely tied to the central nervous system, and linoleate-derived  
405 oxylipins have been identified as the dominant form in the developing rat brain [40]. Like long  
406 chain PUFAs, LA-derived epoxides and diols can also modulate vascular tone [41] and multiple  
407 studies point towards their cytotoxic and pro-inflammation nature. However most of these  
408 studies used concentrations greatly exceeding physiological levels [42] and cytotoxic effects  
409 were sEH-dependent, pointing towards LA diols as cytotoxic agents [43]. Interestingly, LA  
410 CYP/sEH metabolites elevated in the spinal tissue of burn victims were shown to activate the  
411 transient vanilloid receptor type 1 (TRPV1) [44]. Activation of the TRPV1 can rescue neuronal  
412 function from A $\beta$ -induce impairment [45] and can alleviates cognitive and synaptic plasticity  
413 impairments in the *APP23/PS45* mouse model of AD [46]. Considering that acylethanolamides  
414 are also potent activators of the TRPV1 [47], increased LA CYP metabolites may compensate  
415 for the AD-related decrease in these ethanolamides. This hypothesis is supported by positive  
416 correlation of CSF LA-epoxides with the MoCA score in the AD patients, suggesting elevation  
417 of epoxy fatty acids in the central nervous system being potentially beneficial in AD. It is  
418 important to mention that the transportation of oxylipins in CSF is poorly understood. In plasma,  
419 the majority of oxylipins are transported as complex lipid esters in lipoproteins, with different  
420 lipoproteins manifesting distinct oxylipin compositions [48]. Therefore, the potential for

421 lipoprotein-dependent oxylipin transport within CSF specific HDL particles [49] is particularly  
422 intriguing and warrants further investigation.

423 Together the CSF and plasma results implicate changes in both peripheral and central  
424 CYP/sEH metabolism in association with AD and cognitive impairment. These conclusions are  
425 consistent with previous reports of single nucleotide polymorphisms (SNPs) in the CYP2J2  
426 promoter region that reduces gene expression by ~50% that appears to increase the ApoE4-  
427 independent AD risk [50]. Several functional SNPs are also known to influence sEH activity  
428 and/or expression and influence disease risk [51]. Relevant to AD-associated pathologies, loss of  
429 function sEH mutations protect neurons from ischemia-induced death [52] and may alter the risk  
430 of vascular cognitive impairment [53]. Additionally, postmortem brains from human subjects  
431 with AD show higher sEH levels, when compared to the healthy controls, and sEH inhibitors can  
432 reverse microglia and astrocyte reactivity and immune pathway dysregulation in mouse AD  
433 models [31]. Additionally, brain sEH was positively associated with AD in a replicated protein  
434 wide-association study of AD [54]. Therefore, reducing sEH function appears to be protective,  
435 and supports sEH as a valuable therapeutic target for the treatment and investigation of neuro-  
436 inflammatory pathologies including AD.

437 Both plasma and CSF acylethanolamides were lower in AD, with both PLS-DA and  
438 predictive model identifying OEA as the strongest predictor of AD in the current cohort.  
439 Acylethanolamides are generally considered anti-inflammatory [55] and neuroprotective [56]  
440 and were previously implicated in neuroinflammatory processes [57]. Their neuroprotective  
441 action is mediated by activation of the CB1 and CB2 receptors [58] and TRPV1, involved in the  
442 acute and inflammatory pain signals in periphery [59]. Some acylethanolamides, like OEA, are  
443 also peroxisome proliferator-activated receptor (PPAR)  $\alpha$  agonist [58] and regulate satiety and

444 sleep with both central and peripheral anorexigenic effects. Notably, sleep disturbances  
445 themselves have been reported to be a risk factor for AD [60], and the identified reductions in  
446 CSF OEA would be consistent with such a physiological manifestation [61]. A recent study also  
447 suggested that the EPA-derived ethanolamide (EPEA) is a potential PPAR  $\gamma$  agonist [62], a  
448 transcription factor known for its neuroprotective and anti-inflammatory action [63].  
449 Interestingly, non-fasting levels of EPEA showed positive association with MoCA in AD  
450 patients. This is in agreement with our previous findings of acylethanolamides in non-fasted  
451 individuals, including EPEA, being positively associated with perceptual speed in cognitively  
452 normal elderly individuals [19]. Literature provides conflicting results regarding both the levels  
453 of acylethanolamides in biological fluids, as well as the expression of CB1 and CB2 receptors in  
454 the context of AD [64]. Nevertheless, the body of literature suggests that exogenous  
455 cannabinoids are potent activators of the CB1 and CB2 receptors with potential therapeutic  
456 benefit for AD treatment, due to their neuroprotective and anti-inflammatory activity [65]. Our  
457 data suggest acylethanolamide biology is altered in relation to both AD pathology as well as  
458 cognition. However, future studies are needed to fully elaborate the role of these  
459 endocannabinoids in AD pathology.

460         In conclusion, the current study shows AD related differences in CYP/sEH and  
461 acylethanolamide metabolism observed in both plasma and CSF. Strong predictive and  
462 discriminant models suggest their potential as biomarkers of AD-associated metabolic  
463 disruptions. This further supports the contention that a combination therapy reducing sEH  
464 activity while increasing acylethanolamide tone by either promoting production or reducing  
465 degradation could be a more effective strategy than targeting either pathway independently in  
466 treating multifactorial inflammatory diseases like AD [31]. Important questions remain regarding

467 the metabolic changes in the lipid mediators preceding pathological changes in tau and cognitive  
468 decline. We have previously reported that plasma sEH metabolites of the long chain omega-3  
469 PUFA were negatively associated and PUFA ethanolamides positively associated with  
470 perceptual speed [19], mimicking the currently described AD related associations. While these  
471 data suggest early alterations in these important regulatory pathways, a comprehensive analysis  
472 of longitudinal metabolome changes in relation to cognition and tauopathies is warranted.  
473 Combining assessments of dietary, lifestyle and genetic factors promoting these metabolic  
474 changes offers the opportunity for novel risk factor discovery and the development of targeted  
475 preventive measures.

476

477 **Limitations:**

478 This study was conducted using opportunistically collected samples with the fasting state  
479 estimated using a previously developed predictive model [19] with an ~17% inherent  
480 misclassification rate.

481

482 **Acknowledgements:**

483 Metabolomics data is provided by the Alzheimer's Disease Metabolomics Consortium (ADMC)  
484 and funded wholly or in part by the following National Institute on Aging grants and  
485 supplements, components of the Accelerating Medicines Partnership for AD (AMP-AD) and/or  
486 Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD): NIA R01AG046171,  
487 RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359,  
488 U19AG063744 and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke

489 University in partnership with a large number of academic institutions. As such, the investigators  
490 within the ADMC, not listed specifically in this publication's author's list, provided data but did  
491 not participate in analysis or writing of this manuscript. A complete listing of ADMC  
492 investigators can be found at: <https://sites.duke.edu/adnimetab/team/>. Metabolomics data and  
493 pre-processed data are accessible through the AMP-AD Knowledge Portal  
494 (<https://ampadportal.org>). The AMP-AD Knowledge Portal is the distribution site for data,  
495 analysis results, analytical methodology and research tools generated by the AMP-AD Target  
496 Discovery and Preclinical Validation Consortium and multiple Consortia and research programs  
497 supported by the National Institute on Aging. Additional support was provided by Emory ADRC  
498 P30 AG066511 awarded to Allan I. Levey, Emory EHBS R01 AG070937 awarded to James J.  
499 Lah and USDA Intramural Projects 2032-51530-022-00D and 2032-51530-025-00D awarded to  
500 John W. Newman. The USDA is an equal opportunity employer and provider.

501 **Conflicts of Interest:** none

502 Kaddurah-Daouk is an inventor on several patents in the field of metabolomics and holds equity  
503 in Metabolon Inc which was not involved in this study.

## 504 **References**

505

- 506 1. Alkan, E., et al., *Metabolic syndrome alters relationships between cardiometabolic variables,*  
507 *cognition and white matter hyperintensity load.* Sci Rep, 2019. **9**(1): p. 4356.
- 508 2. Bosia, M., et al., *Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of*  
509 *Metabolic Syndrome on Cognitive Remediation's Outcome.* Front Psychiatry, 2018. **9**: p. 647.
- 510 3. Monthe-Dreze, C., et al., *Maternal obesity and offspring cognition: the role of inflammation.*  
511 *Pediatr Res*, 2019. **85**(6): p. 799-806.
- 512 4. Gabbs, M., et al., *Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.* Adv  
513 *Nutr*, 2015. **6**(5): p. 513-40.
- 514 5. Nayeem, M.A., *Role of oxylipins in cardiovascular diseases.* Acta Pharmacol Sin, 2018. **39**(7): p.  
515 1142-1154.

- 516 6. Huang, C.C., et al., *Association of Arachidonic Acid-derived Lipid Mediators with Subsequent*  
517 *Onset of Acute Myocardial Infarction in Patients with Coronary Artery Disease*. *Sci Rep*, 2020.  
518 **10**(1): p. 8105.
- 519 7. Ma, H. and M.E. Patti, *Bile acids, obesity, and the metabolic syndrome*. *Best Pract Res Clin*  
520 *Gastroenterol*, 2014. **28**(4): p. 573-83.
- 521 8. Bellocchio, L., et al., *The endocannabinoid system and energy metabolism*. *J Neuroendocrinol*,  
522 2008. **20**(6): p. 850-7.
- 523 9. Zou, S. and U. Kumar, *Cannabinoid Receptors and the Endocannabinoid System: Signaling and*  
524 *Function in the Central Nervous System*. *Int J Mol Sci*, 2018. **19**(3).
- 525 10. Chiurchiu, V., et al., *The endocannabinoid system and its therapeutic exploitation in multiple*  
526 *sclerosis: Clues for other neuroinflammatory diseases*. *Prog Neurobiol*, 2018. **160**: p. 82-100.
- 527 11. Chiang, J.Y., *Bile acid metabolism and signaling*. *Compr Physiol*, 2013. **3**(3): p. 1191-212.
- 528 12. Guo, C., W.D. Chen, and Y.D. Wang, *TGR5, Not Only a Metabolic Regulator*. *Front Physiol*, 2016.  
529 **7**: p. 646.
- 530 13. Bazan, N.G., V. Colangelo, and W.J. Lukiw, *Prostaglandins and other lipid mediators in*  
531 *Alzheimer's disease*. *Prostaglandins Other Lipid Mediat*, 2002. **68-69**: p. 197-210.
- 532 14. Kao, Y.C., et al., *Lipids and Alzheimer's Disease*. *Int J Mol Sci*, 2020. **21**(4).
- 533 15. Miyazawa, K., et al., *Alzheimer's Disease and Specialized Pro-Resolving Lipid Mediators: Do*  
534 *MaR1, RvD1, and NPD1 Show Promise for Prevention and Treatment?* *Int J Mol Sci*, 2020. **21**(16).
- 535 16. MahmoudianDehkordi, S., et al., *Altered bile acid profile associates with cognitive impairment in*  
536 *Alzheimer's disease-An emerging role for gut microbiome*. *Alzheimers Dement*, 2019. **15**(1): p.  
537 76-92.
- 538 17. Baloni, P., et al., *Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism*  
539 *in Alzheimer's Disease*. *Cell Rep Med*, 2020. **1**(8): p. 100138.
- 540 18. Ackerman, H.D. and G.S. Gerhard, *Bile Acids in Neurodegenerative Disorders*. *Front Aging*  
541 *Neurosci*, 2016. **8**: p. 263.
- 542 19. Borkowski, K.e.a., *Serum metabolomic biomarkers of perceptual speed in cognitively normal and*  
543 *mildly impaired subjects with fasting state stratification*.  
544 <https://doi.org/10.1101/2020.09.03.282343>, 2020.
- 545 20. Goetz, M.E., et al., *Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain*  
546 *Studies*. *Neuroepidemiology*, 2019. **53**(3-4): p. 187-200.
- 547 21. Shaw, L.M., et al., *Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging*  
548 *initiative subjects*. *Ann Neurol*, 2009. **65**(4): p. 403-13.
- 549 22. Hulstaert, F., et al., *Improved discrimination of AD patients using beta-amyloid(1-42) and tau*  
550 *levels in CSF*. *Neurology*, 1999. **52**(8): p. 1555-62.
- 551 23. Pedersen, T.L., I.J. Gray, and J.W. Newman, *Plasma and serum oxylipin, endocannabinoid, bile*  
552 *acid, steroid, fatty acid and nonsteroidal anti-inflammatory drug quantification in a 96-well plate*  
553 *format*. *Anal Chim Acta*, 2021. **1143**: p. 189-200.
- 554 24. Agrawal, K., et al., *Sweat lipid mediator profiling: a noninvasive approach for cutaneous*  
555 *research*. *J Lipid Res*, 2017. **58**(1): p. 188-195.
- 556 25. Saito, K., et al., *Characterization of Postprandial Effects on CSF Metabolomics: A Pilot Study with*  
557 *Parallel Comparison to Plasma*. *Metabolites*, 2020. **10**(5).
- 558 26. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and Powerful*  
559 *Approach to Multiple Testing*. *Journal of the Royal Statistical Society. Series B (Methodological)*,  
560 1995. **57**(1): p. 289-300.
- 561 27. Lee, C.R., et al., *Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart*  
562 *disease: The Atherosclerosis Risk in Communities (ARIC) study*. *Hum Mol Genet*, 2006. **15**(10): p.  
563 1640-9.



- 564 28. Jahn, D. and A. Geier, *Bile acids in nonalcoholic steatohepatitis: Pathophysiological driving force*  
565 *or innocent bystanders?* Hepatology, 2018. **67**(2): p. 464-466.
- 566 29. Grant, S.M. and S. DeMorrow, *Bile Acid Signaling in Neurodegenerative and Neurological*  
567 *Disorders*. Int J Mol Sci, 2020. **21**(17).
- 568 30. Neu, S.C., et al., *Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-*  
569 *analysis*. JAMA Neurol, 2017. **74**(10): p. 1178-1189.
- 570 31. Ghosh A, e.a., *Epoxy fatty acid dysregulation and neuroinflammation in Alzheimer's disease is*  
571 *resolved by a soluble epoxide hydrolase inhibitor*. BioRxiv doi:  
572 <https://doi.org/10.1101/2020.06.30.180984>.
- 573 32. Kodani, S.D. and C. Morisseau, *Role of epoxy-fatty acids and epoxide hydrolases in the pathology*  
574 *of neuro-inflammation*. Biochimie, 2019. **159**: p. 59-65.
- 575 33. Deng, Y., K.N. Theken, and C.R. Lee, *Cytochrome P450 epoxygenases, soluble epoxide hydrolase,*  
576 *and the regulation of cardiovascular inflammation*. J Mol Cell Cardiol, 2010. **48**(2): p. 331-41.
- 577 34. Ulu, A., et al., *Anti-inflammatory effects of omega-3 polyunsaturated fatty acids and soluble*  
578 *epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension*. J Cardiovasc Pharmacol,  
579 2013. **62**(3): p. 285-97.
- 580 35. Imig, J.D. and B.D. Hammock, *Soluble epoxide hydrolase as a therapeutic target for*  
581 *cardiovascular diseases*. Nat Rev Drug Discov, 2009. **8**(10): p. 794-805.
- 582 36. Wagner, K.M., et al., *Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory*  
583 *and neurodegenerative diseases*. Pharmacol Ther, 2017. **180**: p. 62-76.
- 584 37. Firoz, C.K., et al., *An overview on the correlation of neurological disorders with cardiovascular*  
585 *disease*. Saudi J Biol Sci, 2015. **22**(1): p. 19-23.
- 586 38. Klett, E.L., et al., *Diminished acyl-CoA synthetase isoform 4 activity in INS 832/13 cells reduces*  
587 *cellular epoxyeicosatrienoic acid levels and results in impaired glucose-stimulated insulin*  
588 *secretion*. J Biol Chem, 2013. **288**(30): p. 21618-29.
- 589 39. Greene, J.F., et al., *Metabolism of monoepoxides of methyl linoleate: bioactivation and*  
590 *detoxification*. Arch Biochem Biophys, 2000. **376**(2): p. 420-32.
- 591 40. Hennebelle, M., et al., *Linoleic acid-derived metabolites constitute the majority of oxylipins in the*  
592 *rat pup brain and stimulate axonal growth in primary rat cortical neuron-glia co-cultures in a*  
593 *sex-dependent manner*. J Neurochem, 2020. **152**(2): p. 195-207.
- 594 41. Takahashi, H., et al., *[Leukotoxin, 9,10-epoxy-12-octadecenoate, causes vasodilation in isolated*  
595 *pulmonary artery rings precontracted with endothelin 1]*. Nihon Kyobu Shikkan Gakkai Zasshi,  
596 1992. **30**(3): p. 418-24.
- 597 42. Hildreth, K., et al., *Cytochrome P450-derived linoleic acid metabolites EpOMEs and DiHOMEs: a*  
598 *review of recent studies*. J Nutr Biochem, 2020. **86**: p. 108484.
- 599 43. Moghaddam, M.F., et al., *Bioactivation of leukotoxins to their toxic diols by epoxide hydrolase*.  
600 Nat Med, 1997. **3**(5): p. 562-6.
- 601 44. Green, D., et al., *Central activation of TRPV1 and TRPA1 by novel endogenous agonists*  
602 *contributes to mechanical allodynia and thermal hyperalgesia after burn injury*. Mol Pain, 2016.  
603 **12**.
- 604 45. Balleza-Tapia, H., et al., *TrpV1 receptor activation rescues neuronal function and network*  
605 *gamma oscillations from Abeta-induced impairment in mouse hippocampus in vitro*. Elife, 2018.  
606 **7**.
- 607 46. Du, Y., et al., *TRPV1 activation alleviates cognitive and synaptic plasticity impairments through*  
608 *inhibiting AMPAR endocytosis in APP23/PS45 mouse model of Alzheimer's disease*. Aging Cell,  
609 2020. **19**(3): p. e13113.

- 610 47. Raboune, S., et al., *Novel endogenous N-acyl amides activate TRPV1-4 receptors, BV-2 microglia,*  
611 *and are regulated in brain in an acute model of inflammation.* Front Cell Neurosci, 2014. **8**: p.  
612 195.
- 613 48. Borkowski, K., et al., *Walnuts change lipoprotein composition suppressing TNFalpha-stimulated*  
614 *cytokine production by diabetic adipocyte.* J Nutr Biochem, 2019. **68**: p. 51-58.
- 615 49. Mahley, R.W., *Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol*  
616 *Metabolism.* Arterioscler Thromb Vasc Biol, 2016. **36**(7): p. 1305-15.
- 617 50. Yan, H.C., et al., *CYP2J2 rs890293 polymorphism is associated with susceptibility to Alzheimer's*  
618 *disease in the Chinese Han population.* Neuroscience Letters, 2015. **593**: p. 56-60.
- 619 51. Srivastava, P.K., et al., *Polymorphisms in human soluble epoxide hydrolase: effects on enzyme*  
620 *activity, enzyme stability, and quaternary structure.* Arch Biochem Biophys, 2004. **427**(2): p. 164-  
621 9.
- 622 52. Koerner, I.P., et al., *Polymorphisms in the human soluble epoxide hydrolase gene EPHX2 linked to*  
623 *neuronal survival after ischemic injury.* J Neurosci, 2007. **27**(17): p. 4642-9.
- 624 53. Nelson, J.W., et al., *Role of soluble epoxide hydrolase in age-related vascular cognitive decline.*  
625 *Prostaglandins Other Lipid Mediat*, 2014. **113-115**: p. 30-7.
- 626 54. Wingo, A.P., et al., *Integrating human brain proteomes with genome-wide association data*  
627 *implicates new proteins in Alzheimer's disease pathogenesis.* Nat Genet, 2021. **53**(2): p. 143-146.
- 628 55. Turcotte, C., et al., *Regulation of inflammation by cannabinoids, the endocannabinoids 2-*  
629 *arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites.* J Leukoc Biol,  
630 2015. **97**(6): p. 1049-70.
- 631 56. Petrosino, S. and V. Di Marzo, *The pharmacology of palmitoylethanolamide and first data on the*  
632 *therapeutic efficacy of some of its new formulations.* Br J Pharmacol, 2017. **174**(11): p. 1349-  
633 1365.
- 634 57. Saito, V.M., R.M. Rezende, and A.L. Teixeira, *Cannabinoid modulation of neuroinflammatory*  
635 *disorders.* Curr Neuropharmacol, 2012. **10**(2): p. 159-66.
- 636 58. Bradshaw, H.B. and J.M. Walker, *The expanding field of cannabimimetic and related lipid*  
637 *mediators.* Br J Pharmacol, 2005. **144**(4): p. 459-65.
- 638 59. Bradshaw, H.B., S. Raboune, and J.L. Hollis, *Opportunistic activation of TRP receptors by*  
639 *endogenous lipids: exploiting lipidomics to understand TRP receptor cellular communication.* Life  
640 Sci, 2013. **92**(8-9): p. 404-9.
- 641 60. Li, K., et al., *Interactions between sleep disturbances and Alzheimer's disease on brain function: a*  
642 *preliminary study combining the static and dynamic functional MRI.* Sci Rep, 2019. **9**(1): p.  
643 19064.
- 644 61. Koethe, D., et al., *Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.* J  
645 Neural Transm (Vienna), 2009. **116**(3): p. 301-5.
- 646 62. Giordano, C., et al., *n-3 Polyunsaturated Fatty Acid Amides: New Avenues in the Prevention and*  
647 *Treatment of Breast Cancer.* Int J Mol Sci, 2020. **21**(7).
- 648 63. Villapol, S., *Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and Peripheral*  
649 *Inflammation.* Cell Mol Neurobiol, 2018. **38**(1): p. 121-132.
- 650 64. Berry, A.J., et al., *Endocannabinoid system alterations in Alzheimer's disease: A systematic*  
651 *review of human studies.* Brain Res, 2020. **1749**: p. 147135.
- 652 65. Aso, E. and I. Ferrer, *Cannabinoids for treatment of Alzheimer's disease: moving toward the*  
653 *clinic.* Front Pharmacol, 2014. **5**: p. 37.
- 654 66. Pedersen, T.L. and J.W. Newman, *Establishing and Performing Targeted Multi-residue Analysis*  
655 *for Lipid Mediators and Fatty Acids in Small Clinical Plasma Samples.* Methods Mol Biol, 2018.  
656 **1730**: p. 175-212.

657 **Figure legend**

658

659 **Figure 1. Plasma differences in fatty acids-derived oxylipins and endocannabinoids,**  
660 **between control and AD group, projected on their metabolic pathway.** Only differences with  
661 the t-test  $p < 0.05$  and FDR correction at  $q = 0.2$  are shown. Network presents fatty acids metabolic  
662 pathway, including saturates and monounsaturates (SFA and MUFA) and omega 3 and omega 6  
663 fatty acids with oxylipins and endocannabinoids synthesis pathway. Both detected (black font)  
664 and not-detected (gray font) metabolites are shown to visualize the coverage of the metabolic  
665 pathway in our targeted assay and facilitate data interpretation. Although, for the clarity of the  
666 figure, not all assay metabolites are displayed. The complete list of measured metabolites was  
667 previously reported [66]. Oxylipin metabolizing enzymes are colored by their class: red –  
668 lipoxygenase (LOX) and autoxidation pathway; blue – cytochrome p450 (CYP) epoxygenase;  
669 green – cyclooxygenase (COX); yellow – N-acylphosphatidylethanolamide-phospholipase D.  
670 Node size represents the-fold difference, and the color represents the directionality of the  
671 difference: orange – higher in AD; light blue – lower in AD. Key enzymes involved in metabolic  
672 step are abbreviated next to the edge. Fads – fatty acid desaturase; Elov – fatty acids elongase;  
673 sEH – soluble epoxide hydrolase; DH – dehydrogenase. Saturated and monounsaturated fatty  
674 acids were not measured in this assay and are indicated only to visualize precursors for measured  
675 oxylipins and endocannabinoids. Group means for all metabolites together with corresponding t-  
676 test p-values are provided in the **Table S3**.

677

678 **Figure 2. CSF differences in fatty acids-derived oxylipins and endocannabinoids, between**  
679 **control and AD group, projected on their metabolic pathway.** Only differences with the t-  
680 test  $p < 0.05$  and FDR correction at  $q = 0.2$  are shown. Network presents fatty acids metabolic  
681 pathway, including saturates and monounsaturates (SFA and MUFA) and omega 3 and omega 6  
682 fatty acids with oxylipins and endocannabinoids synthesis pathway. For the clarity purposes,  
683 only metabolites detected in CSF are shown. Oxylipin metabolizing enzymes are colored by  
684 their class: red – lipoxygenase (LOX) and autoxidation pathway; blue – cytochrome p450 (CYP)  
685 epoxygenase; green – cyclooxygenase (COX); yellow – N-acylphosphatidylethanolamide-  
686 phospholipase D. Node size represents the-fold difference, and the color represents the  
687 directionality of the difference: orange – higher in AD; light blue – lower in AD. Key enzymes  
688 involved in metabolic step are abbreviated next to the edge. Fads – fatty acid desaturase; Elov –  
689 fatty acids elongase; sEH – soluble epoxide hydrolase; DH – dehydrogenase. Saturated and  
690 monounsaturated fatty acids were not measured in this assay and are indicated only to visualize  
691 precursors for measured oxylipins and endocannabinoids. Group means for all metabolites  
692 together with corresponding t-test p-values are provided in the **Table S4**.

693

694 **Figure 3. Relation between plasma and CSF predictors of AD.** Partial least square  
695 discriminant analysis (PLS-DA) of AD vs control, utilizing metabolites from both plasma and  
696 CSF in predicted fasted samples. Treatment group discrimination is shown by the SCORES  
697 (inset) with a plain of discrimination indicated by dashed red line, while metabolites weighting  
698 in group discrimination are shown by the LOADINGS. Loading node color indicates metabolite  
699 origin (pink for plasma and blue for CSF). Loading node size indicates metabolite variable

700 importance in projection (i.e. VIP). Analysis was performed with all measured metabolites,  
701 including specific ratios, but only those with  $VIP \geq 1.4$  are displayed for clarity purpose.

702

703 **Figure 4. Predictive model for AD with plasma and CSF metabolites.** Predictive model built  
704 independently for plasma (left) and CSF (middle) and plasma+CSF (right). Effect summary  
705 shows metabolite model components, sorted by their contribution to the model, with key  
706 pathway colored in yellow (fatty acids ethanolamides) and blue (cytochrome p450/soluble  
707 epoxide hydrolase pathway). Receiver operating characteristics (ROC) curve for the training set,  
708 together with the area under the curve (AUC) and the n for the training (T) and the validation (V)  
709 cohorts, are showed in the bottom panel. Metabolite selection through the stepwise logistic  
710 regression model together with validation cohort parameters are provided in the **Table S6**.

711

712

713

714

715

716

717

718

719

720 **Tables**721 **Table 1. Differences in bile acids metabolites and their specific ratios between control and AD**722 **group.** Means are expressed in nM or as a ratio of the concentrations. Metabolites and their ratio are723 stratified by the metabolic affiliations. All tested bile acids and their ratios are presented in the **Table S3.**

Metabolite	P value	Mean [95%CI]	
		Control	AD
<i>Neutral vs acidic synthesis pathway</i>			
CA	<b>0.0321</b>	27.4 [20.8 - 36.2]	19.3 [13.6 - 27.4]
CDCA	0.978	38.7 [29.2 - 51.5]	46.7 [32.6 - 66.9]
CA/CDCA	<b>0.0008</b>	0.707 [0.571 - 0.876]	0.363 [0.271 - 0.487]
GCDCA/GDCA	0.5	2.08 [1.66 - 2.61]	1.97 [1.51 - 2.57]
TDCA/TLCA	<b>0.0114</b>	1.33 [1.1 - 1.62]	1.81 [1.49 - 2.21]
<i>Conjugation, neutral synthesis pathway</i>			
GDCA/DCA	<b>0.0031</b>	0.719 [0.604 - 0.856]	1.05 [0.836 - 1.33]
TDCA/DCA	0.1	0.0605 [0.0467 - 0.0783]	0.0777 [0.0556 - 0.109]
GCA/CA	<b>0.0104</b>	2.52 [1.86 - 3.39]	4.13 [2.84 - 6.01]
TCA/CA	0.076	0.506 [0.358 - 0.716]	0.711 [0.434 - 1.16]
<i>Conjugation, acidic synthesis pathway</i>			
GUDCA/UDCA	0.7	0.546 [0.341 - 0.876]	0.515 [0.334 - 0.793]
TUDCA/UDCA	0.746	2.83 [1.93 - 4.17]	2.04 [1.33 - 3.13]
GCDCA/CDCA	0.491	8.15 [6.21 - 10.7]	8.36 [5.68 - 12.3]
TCDC/CDCA	0.644	0.734 [0.53 - 1.01]	0.687 [0.433 - 1.09]
TLCA/LCA	0.961	0.282 [0.2 - 0.396]	0.252 [0.182 - 0.347]
GLCA/LCA	0.721	0.711 [0.53 - 0.955]	0.749 [0.552 - 1.02]
<i>Conversion of primary to secondary. Gut metagenome activity</i>			
DCA/CA	<b>0.0459</b>	8.01 [5.8 - 11.1]	12 [7.89 - 18.1]
TDCA/CA	<b>0.0056</b>	0.469 [0.309 - 0.711]	0.906 [0.517 - 1.59]
GDCA/CA	<b>0.0007</b>	5.76 [4.01 - 8.27]	12.5 [7.71 - 20.2]
LCA/CDCA	0.451	0.66 [0.419 - 1.04]	0.589 [0.42 - 0.825]
UDCA/CDCA	0.691	1.39 [0.815 - 2.36]	1.94 [1.23 - 3.07]
TUDCA	<b>0.0275</b>	1.07 [0.78 - 1.48]	1.92 [1.53 - 2.41]

724

725

726 **Table 2.** Spearman's rank order correlation between plasma and CSF metabolites. Significant p  
 727 values are bolded.

Metabolite class	Metabolite	Spearman's $\rho$	P value
<b>Oxylipins</b>	PGF2a	-0.2	0.0746
	F2-IsoP	0.34	<b>0.0019</b>
	12_13-DiHOME	0.26	0.0223
	9_10-DiHOME	0.15	0.1810
	15_16-DiHODE	0.21	0.0625
	14_15-DiHETrE	0.062	0.5830
	11_12-DiHETrE	0.11	0.3340
	17_18-DiHETE	0.33	<b>0.0027</b>
	19_20-DiHD <sub>o</sub> PE	0.16	0.1450
	13-HODE	0.029	0.7970
	9-HODE	-0.054	0.6380
	13-HOTE	-0.014	0.9010
	9-HOTE	-0.051	0.6520
	12(13)-EpOME	0.0089	0.9380
	9(10)-EpOME	-0.028	0.8070
<b>Acyl-EA</b>	OEA	-0.031	0.7820
	LEA	0.062	0.5860
	DHEA	0.51	<b>0.0001</b>
<b>PUFA</b>	LA	0.15	0.1860
	ALA	0.2	0.0826
	AA	-0.049	0.6670
	EPA	0.45	<b>0.0001</b>
	DHA	0.42	<b>0.0001</b>
<b>Bile acids</b>	CDCA	0.51	<b>0.0001</b>
	UDCA	0.78	<b>0.0001</b>
	DCA	0.71	<b>0.0001</b>
	TCA	0.62	<b>0.0001</b>
	TCDCa	0.43	<b>0.0001</b>
	TUDCA	0.16	0.1570
	TDCA	0.54	<b>0.0001</b>
	GCA	0.36	<b>0.0012</b>
	GCDCA	0.19	0.0925
	GUDCA	0.47	<b>0.0001</b>
	GDCA	0.54	<b>0.0001</b>
	GLCA	-0.083	0.4670
<b>Steroids</b>	17OH-PROG	0.58	<b>0.0001</b>
	Cortisol	0.3	<b>0.0071</b>
	Cortexolone	0.089	0.4340
	corticosterone	0.51	<b>0.0001</b>
	Testosterone	0.81	<b>0.0001</b>

728 **Table 3. Spearman's  $\rho$  rank order correlation between MoCA score and plasma lipid**  
 729 **mediators of the AD patients.** Analysis stratified by predicted fasted state. Only correlations  
 730 with the  $p < 0.05$  are shown. P-values that passed FDR correction at  $q = 0.2$  are bolded.

<b>Fasted</b>			<b>Non-fasted</b>		
<b>Metabolite</b>	<b>Spearman <math>\rho</math></b>	<b>P value</b>	<b>Metabolite</b>	<b>Spearman <math>\rho</math></b>	<b>P value</b>
5,15-DiHETE	-0.448	<b>0.0005</b>	EPEA	0.424	<b>0.0003</b>
9-HETE	-0.338	0.0102	EPA	0.386	<b>0.001</b>
13-KODE	-0.299	0.0238	DHA	0.338	<b>0.0043</b>
DCA	-0.273	0.0398	17,18-DiHETE	0.3	0.0117
			4-HDoHE	0.269	0.0246
			LA	0.267	0.0254
			ALA	0.249	0.0373
			9-HETE	-0.246	0.0405
			8-HETE	-0.24	0.0459

731

732

733

734

735

736

737

738

739

740



741 **Table 4. Spearman's  $\rho$  rank order correlation between MoCA score and CSF lipid mediators of**  
742 **the AD patients.** Only correlations with the  $p < 0.05$  are shown. P-values that passed FDR correction at  
743  $q = 0.2$  are bolded.

<b>Metabolite</b>	<b>Spearman <math>\rho</math></b>	<b>P value</b>
12(13)-EpOME	0.279	<b>0.0009</b>
9(10)-EpOME	0.24	<b>0.0047</b>
19,20-DiHDoPE	0.21	0.0138
GCA	0.207	0.0152
DHA	0.203	0.0174
GCA/GDCA	0.202	0.0182
GCDCA/CDCA	0.19	0.026
TDCA/DCA	0.19	0.0261
GCA/GCDCA	0.18	0.0352
TCDCa/CDCA	0.172	0.0441
TCDCa	0.17	0.0468

744

745

746

747

748

749

750

751


752

753

754

755 **Figures**

756



757

758 **Figure 1. Plasma differences in fatty acids-derived oxylipins and endocannabinoids, between**

759 **control and AD group, projected on their metabolic pathway.**

760

761

762

763

764



765

766

**SFA and MUFA**

**Omega-6**

**Omega-3**



767

768 **Figure 2. CSF differences in fatty acids-derived oxylipins and endocannabinoids, between control**  
769 **and AD group, projected on their metabolic pathway.**

770

771

772

773

774

775

776


777

778

779

780

781




782

783 **Figure 3. Relation between plasma and CSF predictors of AD**

784

785



786

787 **Figure 4. Predictive model for AD with plasma and CSF metabolites.** Acylethanolamides

788 shown in gold, CYP/sEH metabolites shown in blue.

789

790

791

792

793


794

795

796

797 **Supplemental figures**

798



799


800 **Figure S1.** Distribution of subject's probability of being in a fasted state in the control and AD  
801 groups. Colors shows 60% probability cutoffs for: red – fasted; blue – non-fasted.

802

803


804

805



806

807 **Figure S2. Bile acids biosynthesis pathway.** Node colors represent primary (blue) and  
 808 secondary (dark red) bile acids. Node shape represent conjugated (diamond) and unconjugated  
 809 (oval) bile acids. Node size represents median concentration in the experimental cohort.  
 810 Cholesterol (top of the pathway) is converted to primary bile acids along two pathways, neutral  
 811 and acidic [1]. Further, primary bile acids are secreted to gut, and portion of it being modify by  
 812 the gut bacteria to secondary bile acids. Primary and secondary bile acids are reabsorbed into the  
 813 blood stream and reenter the liver, where they are conjugated with amino acids glycine or  
 814 taurine. Conjugated bile acids are then being secreted back to the gut along with primary bile  
 815 acids. Gut bacteria can cleave conjugated amino acids off bile acids [2], and freed metabolites  
 816 are recirculated. Therefore, plasma levels of conjugated bile acids can me a reflection of both  
 817 liver and gut bacteria activity. Reference: 1.Pandak, W.M. and G. Kakiyama, The acidic  
 818 pathway of bile acid synthesis: Not just an alternative pathway(). *Liver Res*, 2019. 3(2): p. 88-98;  
 819 2. Ridlon, J.M., et al., Consequences of bile salt biotransformations by intestinal bacteria. *Gut*  
 820 *Microbes*, 2016. 7(1): p. 22-39.



821

822 **Figure S3.** Control and AD group MoCA and log(t-Tau/Aβ42).

823